Cargando…
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.(1)
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245052/ https://www.ncbi.nlm.nih.gov/pubmed/35732146 http://dx.doi.org/10.1016/j.xcrm.2022.100664 |